MX2016004703A - Forma salina de hidrocloruro para la inhibicion de ezh2. - Google Patents

Forma salina de hidrocloruro para la inhibicion de ezh2.

Info

Publication number
MX2016004703A
MX2016004703A MX2016004703A MX2016004703A MX2016004703A MX 2016004703 A MX2016004703 A MX 2016004703A MX 2016004703 A MX2016004703 A MX 2016004703A MX 2016004703 A MX2016004703 A MX 2016004703A MX 2016004703 A MX2016004703 A MX 2016004703A
Authority
MX
Mexico
Prior art keywords
salt form
hydrochloride salt
ezh2 inhibition
methyl
ezh2
Prior art date
Application number
MX2016004703A
Other languages
English (en)
Inventor
Sanders Kristen
Mathieu Steven
W Kuntz Kevin
Choi Hyeong-Wook
Chanda Arani
Original Assignee
Epizyme Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epizyme Inc filed Critical Epizyme Inc
Publication of MX2016004703A publication Critical patent/MX2016004703A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Abstract

Se proporcionan en la presente memoria nuevas formas sólidas de hidrocloruro de N- ((4,6-dimetil-2-oxo1,2-dihidropiridin-3-il)meti l)-5-(etil (tetrahidro-2H-piran-4-il) amino)-4-metil-4´-(morfolino metil)-[1,1´-bifenil]-3-carboxamida y composiciones y métodos relacionados.
MX2016004703A 2013-10-16 2014-10-15 Forma salina de hidrocloruro para la inhibicion de ezh2. MX2016004703A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361891786P 2013-10-16 2013-10-16
PCT/US2014/060724 WO2015057859A1 (en) 2013-10-16 2014-10-15 Hydrochloride salt form for ezh2 inhibition

Publications (1)

Publication Number Publication Date
MX2016004703A true MX2016004703A (es) 2017-02-28

Family

ID=52828660

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016004703A MX2016004703A (es) 2013-10-16 2014-10-15 Forma salina de hidrocloruro para la inhibicion de ezh2.

Country Status (24)

Country Link
US (3) US10040782B2 (es)
EP (2) EP4324525A2 (es)
JP (2) JP6608812B2 (es)
KR (1) KR102142177B1 (es)
CN (1) CN105829302B (es)
AU (2) AU2014337300B2 (es)
CA (1) CA2925889C (es)
CL (1) CL2016000866A1 (es)
DK (1) DK3057962T3 (es)
EA (1) EA038869B1 (es)
ES (1) ES2960953T3 (es)
FI (1) FI3057962T3 (es)
HU (1) HUE063984T2 (es)
IL (1) IL244787B (es)
LT (1) LT3057962T (es)
MA (1) MA38949A1 (es)
MX (1) MX2016004703A (es)
MY (1) MY179802A (es)
PE (1) PE20161273A1 (es)
PL (1) PL3057962T3 (es)
PT (1) PT3057962T (es)
SG (2) SG11201602269QA (es)
SI (1) SI3057962T1 (es)
WO (1) WO2015057859A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3184523T3 (da) 2012-04-13 2019-08-19 Epizyme Inc N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4' -(morphofinomethyl)-[1,1'-biphenyl]-3-carboxamidhydrobromid til anvendelse i behandlingen af en sygdom med celleproliferation i det hæmatologiske system.
KR102142177B1 (ko) 2013-10-16 2020-08-07 에피자임, 인코포레이티드 Ezh2 억제용 하이드로클로라이드 염 형태
IL282741B2 (en) 2013-12-06 2024-01-01 Epizyme Inc Tazematostat in combination with an acceptable treatment factor for use in the treatment of cancer
KR20230031963A (ko) 2014-06-17 2023-03-07 에피자임, 인코포레이티드 림프종 치료를 위한 ｅｚｈ2 억제제
CN112168967A (zh) 2014-10-16 2021-01-05 Epizyme股份有限公司 治疗癌症的方法
KR102644844B1 (ko) * 2014-11-17 2024-03-07 에피자임, 인코포레이티드 암을 치료하기 위한 방법
SG10201902664RA (en) 2015-04-20 2019-04-29 Epizyme Inc Combination therapy for treating cancer
JP6890097B2 (ja) 2015-06-10 2021-06-18 エピザイム，インコーポレイティド リンパ腫を処置するためのｅｚｈ２阻害剤
CN108025191A (zh) 2015-08-24 2018-05-11 Epizyme股份有限公司 治疗癌症的方法
EP3407978A4 (en) 2016-01-29 2020-01-15 Epizyme Inc COMBINATION THERAPY FOR TREATING CANCER
AU2017273726B2 (en) 2016-06-01 2023-10-19 Epizyme, Inc. Use of EZH2 inhibitors for treating cancer
US11147819B2 (en) 2016-06-17 2021-10-19 Epizyme, Inc. EZH2 inhibitors for treating cancer
BR112019014924A2 (pt) 2017-01-19 2020-03-31 St. Marianna University School Of Medicine Composição farmacêutica usada para o tratamento de mielopatia associada ao htlv-1
WO2018183885A1 (en) 2017-03-31 2018-10-04 Epizyme, Inc. Combination therapy for treating cancer
CN110944628A (zh) 2017-06-02 2020-03-31 Epizyme股份有限公司 使用ezh2抑制剂治疗癌症
WO2019050924A1 (en) 2017-09-05 2019-03-14 Epizyme, Inc. POLY THERAPY FOR THE TREATMENT OF CANCER
WO2020011607A1 (en) 2018-07-09 2020-01-16 Fondation Asile Des Aveugles Inhibition of prc2 subunits to treat eye disorders
WO2021035194A1 (en) 2019-08-22 2021-02-25 Juno Therapeutics, Inc. Combination therapy of a t cell therapy and an enhancer of zeste homolog 2 (ezh2) inhibitor and related methods
TW202400140A (zh) 2022-04-27 2024-01-01 日商第一三共股份有限公司 抗體-藥物結合物與ezh1及/或ezh2抑制劑之組合

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0733729A (ja) 1993-07-26 1995-02-03 Kirin Brewery Co Ltd Ｎ−シアノ−ｎ′−置換−アリールカルボキシイミダミド化合物の製造法
NZ277556A (en) 1993-12-27 1997-06-24 Eisai Co Ltd N-phenyl(alkyl)- and n-pyridyl(alkyl)anthranilic acid derivatives; intermediates
DE19516776A1 (de) 1995-05-10 1996-11-14 Boehringer Ingelheim Int Chromatin-Regulatorgene
US5741819A (en) 1995-06-07 1998-04-21 3-Dimensional Pharmaceuticals, Inc. Arylsulfonylaminobenzene derivatives and the use thereof as factor Xa inhibitors
JP3906935B2 (ja) 1995-12-18 2007-04-18 杏林製薬株式会社 Ｎ−置換ジオキソチアゾリジルベンズアミド誘導体及びその製造法
BR9914207A (pt) 1998-09-30 2001-07-03 Procter & Gamble Ceto-amidas 2-substituìdas
UA71587C2 (uk) 1998-11-10 2004-12-15 Шерінг Акцієнгезелльшафт Аміди антранілової кислоти та їхнє застосування як лікарських засобів
US6710058B2 (en) 2000-11-06 2004-03-23 Bristol-Myers Squibb Pharma Company Monocyclic or bicyclic carbocycles and heterocycles as factor Xa inhibitors
WO2002053543A1 (fr) 2000-12-28 2002-07-11 Shionogi & Co., Ltd. Derive de pyridone ayant une affinite pour le recepteur cannabinoide de type 2
US7700293B2 (en) 2001-08-02 2010-04-20 The Regents Of The University Of Michigan Expression profile of prostate cancer
WO2003070277A1 (fr) 2002-02-19 2003-08-28 Shionogi & Co., Ltd. Antiprurigineux
TW200306155A (en) 2002-03-19 2003-11-16 Du Pont Benzamides and advantageous compositions thereof for use as fungicides
US7442685B2 (en) 2003-06-13 2008-10-28 The University Of North Carolina At Chapel Hill DOT1 histone methyltransferases as a target for identifying therapeutic agents for leukemia
US7563589B2 (en) 2004-06-01 2009-07-21 The University Of North Carolina At Chapel Hill Reconstituted histone methyltransferase complex and methods of identifying modulators thereof
JO2787B1 (en) 2005-04-27 2014-03-15 امجين إنك, Alternative amide derivatives and methods of use
DE602006019423D1 (de) 2005-06-02 2011-02-17 Univ North Carolina Reinigung, charakterisierung und wiederherstellung einer ubiquitin-e3-ligase
FR2889526B1 (fr) 2005-08-04 2012-02-17 Aventis Pharma Sa 7-aza-indazoles substitues, compositions les contenant, procede de fabrication et utilisation
SI1940821T1 (sl) 2005-10-19 2013-07-31 Gruenenthal Gmbh Novi vaniloidni receptorski ligandi in njihova uporaba za proizvodnjo zdravil
CA2626402C (en) 2005-10-21 2011-02-15 Merck & Co., Inc. Potassium channel inhibitors
JP5078901B2 (ja) 2005-10-28 2012-11-21 ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル ＪｍｊＣドメインを含むタンパク質デメチラーゼ
WO2007070818A1 (en) 2005-12-14 2007-06-21 Bristol-Myers Squibb Company Six-membered heterocycles useful as serine protease inhibitors
AU2006336552B2 (en) 2006-01-20 2012-12-20 The University Of North Carolina At Chapel Hill Diagnostic and therapeutic targets for leukemia
JP2009537521A (ja) 2006-05-15 2009-10-29 アイアールエム・リミテッド・ライアビリティ・カンパニー テレフタラメート化合物および組成物、ならびにｈｉｖインテグラーゼ阻害剤としてのそれらの使用
US20070287706A1 (en) 2006-05-18 2007-12-13 Dickson John K Jr Certain substituted quinolones, compositions, and uses thereof
US8022246B2 (en) 2006-10-10 2011-09-20 The Burnham Institute For Medical Research Neuroprotective compositions and methods
AU2008219166B2 (en) 2007-02-16 2013-05-16 Amgen Inc. Nitrogen-containing heterocyclyl ketones and their use as c-Met inhibitors
WO2008104077A1 (en) 2007-02-28 2008-09-04 Methylgene Inc. Small molecule inhibitors of protein arginine methyltransferases (prmts)
WO2008113006A1 (en) 2007-03-14 2008-09-18 Xenon Pharmaceuticals Inc. Methods of using quinolinone compounds in treating sodium channel-mediated diseases or conditions
DE102007017884A1 (de) 2007-04-13 2008-10-16 Grünethal GmbH Neue Vanilloid-Rezeptor Liganden und ihre Verwendung zur Herstellung von Arzneimitteln
WO2009006577A2 (en) 2007-07-03 2009-01-08 The Regents Of The University Of Michigan Compositions and methods for inhibiting ezh2
CA2703909A1 (en) 2007-10-31 2009-05-07 Merck Sharp & Dohme Corp. P2x3, receptor antagonists for treatment of pain
ES2520940T3 (es) 2007-12-19 2014-11-12 Cancer Research Technology Limited Compuestos de pirido[2,3-b]pirazina 8-sustituida y su uso
WO2009124137A2 (en) 2008-04-01 2009-10-08 Mount Sinai School Of Medicine Of New York University Method of suppressing gene transcription through histone lysine methylation
US20100113415A1 (en) 2008-05-29 2010-05-06 Rajapakse Hemaka A Epha4 rtk inhibitors for treatment of neurological and neurodegenerative disorders and cancer
EP2323660A2 (en) 2008-08-08 2011-05-25 New York Blood Center Small molecule inhibitors of retroviral assembly and maturation
FR2934995B1 (fr) 2008-08-14 2010-08-27 Sanofi Aventis Composes d'azetidines polysubstitues, leur preparation et leur application en therapeutique
WO2010111653A2 (en) 2009-03-27 2010-09-30 The Uab Research Foundation Modulating ires-mediated translation
US20110021362A1 (en) 2009-07-20 2011-01-27 Constellation Pharmaceuticals Agents for stimulating activity of methyl modifying enzymes and methods of use thereof
EP2521558A4 (en) 2009-12-30 2013-07-03 Avon Prod Inc TOPICAL LIGHTING COMPOSITION AND USES THEREOF
EP2566479B1 (en) 2010-05-07 2014-12-24 GlaxoSmithKline LLC Azaindazoles
SI2566327T1 (sl) 2010-05-07 2017-07-31 Glaxosmithkline Llc Indoli
US8846935B2 (en) 2010-05-07 2014-09-30 Glaxosmithkline Llc Indazoles
US9175331B2 (en) * 2010-09-10 2015-11-03 Epizyme, Inc. Inhibitors of human EZH2, and methods of use thereof
KR102061353B1 (ko) 2010-09-10 2020-01-02 에피자임, 인코포레이티드 인간 ｅｚｈ2의 억제제 및 이의 사용 방법
US20130310379A1 (en) 2010-11-19 2013-11-21 Constellation Pharmaceuticals Modulators of methyl modifying enzymes, compositions and uses thereof
US8765792B2 (en) 2010-12-01 2014-07-01 Glaxosmithkline Llc Indoles
WO2012075500A2 (en) 2010-12-03 2012-06-07 Epizyme, Inc. 7-deazapurine modulators of histone methyltransferase, and methods of use thereof
AU2012223448B2 (en) 2011-02-28 2017-03-16 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
JO3438B1 (ar) 2011-04-13 2019-10-20 Epizyme Inc مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
TW201733984A (zh) 2011-04-13 2017-10-01 雅酶股份有限公司 經取代之苯化合物
KR102453519B1 (ko) 2012-03-12 2022-10-11 에피자임, 인코포레이티드 인간 ｅｚｈ2의 억제제 및 이의 사용 방법
IL289300B1 (en) 2012-04-13 2024-01-01 Epizyme Inc Combined treatment for cancer
DK3184523T3 (da) 2012-04-13 2019-08-19 Epizyme Inc N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4' -(morphofinomethyl)-[1,1'-biphenyl]-3-carboxamidhydrobromid til anvendelse i behandlingen af en sygdom med celleproliferation i det hæmatologiske system.
WO2013173441A2 (en) 2012-05-16 2013-11-21 Glaxosmithkline Llc Enhancer of zeste homolog 2 inhibitors
LT2908823T (lt) 2012-10-15 2019-10-25 Epizyme Inc Vėžio gydymo būdai
UA115074C2 (uk) 2012-10-15 2017-09-11 Епізайм, Інк. Бензольні сполуки, що містять замісники
US20150344427A1 (en) 2012-12-21 2015-12-03 Epizyme, Inc. 1,4-pyridone compounds
US9701666B2 (en) 2012-12-21 2017-07-11 Epizyme, Inc. 1,4-pyridone bicyclic heteroaryl compounds
CA2903572A1 (en) 2013-03-15 2014-10-23 Epizyme, Inc. Substituted benzene compounds
WO2014144747A1 (en) 2013-03-15 2014-09-18 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
WO2015010049A1 (en) 2013-07-19 2015-01-22 Epizyme, Inc. Substituted benzene compounds
US9624205B2 (en) 2013-07-19 2017-04-18 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
KR102142177B1 (ko) 2013-10-16 2020-08-07 에피자임, 인코포레이티드 Ezh2 억제용 하이드로클로라이드 염 형태

Also Published As

Publication number Publication date
NZ718201A (en) 2021-09-24
JP2019052181A (ja) 2019-04-04
EA201690650A1 (ru) 2016-10-31
JP6608812B2 (ja) 2019-11-20
EA038869B1 (ru) 2021-10-29
SI3057962T1 (sl) 2024-01-31
AU2014337300B2 (en) 2019-01-03
US10040782B2 (en) 2018-08-07
AU2014337300A1 (en) 2016-04-14
KR102142177B1 (ko) 2020-08-07
PT3057962T (pt) 2023-11-07
SG10201901977XA (en) 2019-04-29
WO2015057859A1 (en) 2015-04-23
IL244787A0 (en) 2016-04-21
IL244787B (en) 2022-04-01
CL2016000866A1 (es) 2016-12-23
PL3057962T3 (pl) 2024-01-29
DK3057962T3 (da) 2023-11-06
EP4324525A2 (en) 2024-02-21
SG11201602269QA (en) 2016-04-28
AU2019202246A1 (en) 2019-04-18
FI3057962T3 (fi) 2023-11-03
EP3057962A4 (en) 2017-05-24
HUE063984T2 (hu) 2024-02-28
MY179802A (en) 2020-11-16
CN105829302A (zh) 2016-08-03
LT3057962T (lt) 2023-12-11
KR20160082993A (ko) 2016-07-11
US10710987B2 (en) 2020-07-14
CA2925889C (en) 2020-09-29
EP3057962B1 (en) 2023-10-18
CA2925889A1 (en) 2015-04-23
ES2960953T3 (es) 2024-03-07
US20160237068A1 (en) 2016-08-18
US20180282312A1 (en) 2018-10-04
US20210017163A1 (en) 2021-01-21
CN105829302B (zh) 2020-09-08
JP2016533349A (ja) 2016-10-27
MA38949A1 (fr) 2017-07-31
PE20161273A1 (es) 2016-12-18
EP3057962A1 (en) 2016-08-24

Similar Documents

Publication Publication Date Title
MX2016004703A (es) Forma salina de hidrocloruro para la inhibicion de ezh2.
CY1122883T1 (el) Ν-((4,6-διμεθυλ-2-οξο-l,2-διυδροπυριδιν-3-υλ)μεθυλ)-5-(αιθυλ (τετραϋδρο-2η-πυραν-4-υλ)αμινο)-4-μεθυλ-4'-(μορφολινομεθυλ)-[l,1'-διφαινυλ]-3-καρβοξαμιδιο υδροβρωμικο για χρηση στη θεραπεια μιας κυτταροπολλαπλασιαστικης διαταραχης του αιματολογικου συστηματος
DK3220916T3 (da) Fremgangsmåde til behandling af cancer med n-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2h-pyran-4-yl)amino)-4-methyl-4'-(morpholinomethyl)-[1,1'-biphenyl]-3-carboxamid
CY1120703T1 (el) Ετεροκυκλικες ενωσεις και χρησεις αυτων
EA201991884A3 (ru) Ингибиторы g12c kras
EA201690752A1 (ru) Ингибиторы g12c kras
MX2019009501A (es) Compuestos de amino piridina utiles como inhibidores de ssao.
JO3452B1 (ar) بنزاميدات أمينو اريل مغاير كمثبطات كيناز
EA201590748A1 (ru) Противовирусные соединения против rsv
MX366949B (es) Análogos sustituidos de (e)-n'-(1-feniletiliden)benzohidrazida como inhibidores de histona desmetilasa.
EP4219465A3 (en) Prmt5 inhibitors and uses thereof
MX2016011992A (es) Derivados de piperidina-diona.
EA201790395A1 (ru) Производные аминотриазина, подходящие для применения в качестве соединений-ингибиторов tank-связывающей киназы
EA201692249A1 (ru) Ингибиторы фосфатидилинозитол-3-киназы
GEP20166432B (en) 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh
EA201691242A1 (ru) Фармацевтические композиции, содержащие azd9291
EA201692266A1 (ru) Ингибиторы фосфатидилинозитол-3-киназы
MX2015014455A (es) Terapia de combinacion que comprende un inhibidor de tor cinasa y n-(3-(5-fluoro-2-(4-(2-metoxietoxi)fenilamino)pirimidin-4-ilamino )fenil)acrilamida para tratar cancer.
EA029499B9 (ru) Ингибиторы rorc2 и способы их применения
IL273974B1 (en) Amine-disubstituted heterocyclic compounds as ehmt2 inhibitors, salts thereof and method for their synthesis
MY198008A (en) Crystal of benzofuran derivative free base and preparation method
MX2018000175A (es) Compuestos de arilsulfonamida como inhibidores de la anhidrasa carbonica y su uso terapeutico.
EA201391299A1 (ru) Ингибиторы пептиддеформилазы

Legal Events

Date Code Title Description
FG Grant or registration